🇺🇸 FDA
Pipeline program

68Ga-FAPI-46

IC 2022-02

Phase 2 small_molecule active

Quick answer

68Ga-FAPI-46 for Triple-negative breast cancer (TNBC) patients at high risk of relapse is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Triple-negative breast cancer (TNBC) patients at high risk of relapse
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials